Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Somatrogon vs Daily Genotropin in Pre-pubertal Children with Growth Hormone Deficiency
2016-003874-42Phase 3Unknown
- Sponsor
- OPKO Biologics
- Start
- Jan 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatrogon in growth hormone deficiency (GHD) (2 arms), sponsored by OPKO Biologics. Primary endpoint: Annual height velocity. Status: unknown.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2016-003874-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003874-42.